Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trainline an 'underappreciated equity', says Berenberg

(Sharecast News) - Berenberg said on Wednesday that Trainline is an "underappreciated equity" and that it continues to view the company as a top pick in its coverage following full-year results on 7 May. The bank, which maintained its 'buy' rating and 490p price target on the shares, noted that they are down 7% since the results and 40% year-to-date, due largely to concerns around the UK competitive and regulatory landscape.

"While acknowledging there is unlikely to be a big-bang-type catalyst that removes these concerns, we think they are overdone," it said.

"Following the year-to-date de-rating, the shares trade on 12x FY26E price-to-earnings, which we think provides an attractive risk/reward for investors, and ultimately continued strong operational performance will support a re-rating over time," Berenberg said.

It pointed out that in FY25, UK Consumer net ticket sales growth continues to be robust at 13% and International Consumer is now profitable, which is a key milestone for the division.

"FY26E guidance points to 6-9% adjusted EBITDA growth, and combined with the ongoing share buyback, we forecast 15% adjusted EPS growth," the bank said.

Berenberg highlighted attractive cash generation and potential for further shareholder returns. It noted that Trainline has now repurchased £154m of shares since September 2023 and that leverage at year end was 0.5x and there is an ongoing £75m share buyback.

"We forecast £81m of free cash flow in FY26E and we think there is scope for additional buybacks following the completion of the current buyback," it said.

At 1320 BST, the shares were up 6.1% at 268.80p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.